{"commentary":{"count":25,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"podcast":10,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02734004\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MEDIOLA","nct_id":"NCT02734004","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mediola-nct02734004. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MEDIOLA","arms":[{"description":"Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Includes 2nd stage cohorts (modules 5 \\& 7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1","label":"Arm 2","type":"EXPERIMENTAL"},{"description":"Includes 2nd stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1","label":"Arm 3","type":"EXPERIMENTAL"}],"collaborators":["IQVIA Pty Ltd"],"completion_date":{"date":"2026-09-17","type":"ESTIMATED"},"conditions":["Ovarian","Breast","SCLC","Gastric Cancers"],"enrollment":{"count":264,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Olaparib","type":"DRUG"},{"name":"MEDI4736","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"}],"last_update":"2026-07-14","lead_sponsor":"AstraZeneca","official_title":"A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2021-09-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12","timeFrame":"RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019."},{"measure":"Second Stage Cohort: Objective Response Rate (ORR)","timeFrame":"RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021."},{"measure":"Second Stage Cohorts: DCR at Week 24","timeFrame":"RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021."}],"references":[{"citation":"Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249.","pmid":"37939124","type":"DERIVED"},{"citation":"Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022.","pmid":"35756843","type":"DERIVED"},{"citation":"Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.","pmid":"32771088","type":"DERIVED"}],"start_date":{"date":"2016-03-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","url":"https://clinicaltrials.gov/study/NCT02734004"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mediola-nct02734004"}